Comparative seroconversion of foot-and-mouth disease vaccines in goats

Abstract

The comparative seroconversions of two different foot-and-mouth disease vaccines in goats were studied. Group I animals were vaccinated with inactivated quadrivalent aluminium hydroxide gel saponin adjuvanted FMD vaccine. Group 11 animals were vaccinated with inactivated quadrivalent FMD oil-adjuvant vaccine as per the manufacture's schedule. Vaccinations were done in unvaccinated goats above four month of age. The antibody titre against foot and mouth disease virus types 0, A, C and Asia-I were assessed by liquid phase blocking ELISA. Group I animals showed the protective titre of type ° antibody titres throughout the period except sixth, tenth, eleventh and twelfth month. Group 11 animals showed the protective level throughout the study period except seventh, eighth and ninth month. Both the groups showed the protective titre of type A, C and Asia-I antibody titres throughout the study period up to 12 months. All the vaccination including primary and booster vaccinations produce increase in antibody titre. Both the groups did not show any significant variation in antibody titres against FMDV type 0, A, C and Asia-I except the time of booster vaccination. Kids born from both the ~roups showed the protective level of type ° maternal antibody only upto one week of age where as protective level for type A and C maternal antibodies upto four weeks of age. Group I kids maintained the protective level of type Asia-I upto two weeks of age where as Group 11 maintained upto three weeks of age.

From this observation it is concluded that 1. Both the group of vaccine provides sufficient protective titre for FMDV type 0, A, C and Asia-l . 2. Aluminium hydroxide gel vaccine performance is equally good as that of oil adjuvanted vaccine. 3. Oil-adjuvanted vaccine reduces labour cost for injection, number of visit and stress to the animals to a very ?reat extent. Therefore oil-adjuvanted vaccine may be preferred when compared to gel vaccine. 4. The maternal antibody protect the kids which were born to vaccinated does one to four weeks of age, regardless of the adjuvant used in the vaccine.